Literature DB >> 19293790

Editorial: It's time to make organized colorectal cancer screening convenient and easy for patients.

Theodore R Levin.   

Abstract

Colorectal cancer (CRC) screening is widely recommended, but underused. To increase screening rates, we need to implement organized and population-based systems to promote CRC screening among people in a single region, health plan, or health system. This is ideally accomplished using fecal immunochemical tests (FITs), which can be sent through a mass mailing. The study by Levi and colleagues shows that patients using aspirin, non-steroidal anti-inflammatory drugs (NSAIDs), anti-platelet agents, or anti-coagulants do not need to stop these medications while doing the fecal collection. This makes the testing more convenient for patients, and avoids the risk of adverse cardiovascular events caused by stopping these medications.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19293790     DOI: 10.1038/ajg.2009.18

Source DB:  PubMed          Journal:  Am J Gastroenterol        ISSN: 0002-9270            Impact factor:   10.864


  4 in total

1.  Where does it FIT? The roles of fecal testing and colonoscopy in colorectal cancer screening.

Authors:  Grace Clarke Hillyer; Alfred I Neugut
Journal:  Cancer       Date:  2015-05-20       Impact factor: 6.860

2.  Test characteristics of faecal immunochemical tests (FIT) compared with optical colonoscopy.

Authors:  Barcey T Levy; Camden Bay; Yinghui Xu; Jeanette M Daly; George Bergus; Jeffrey Dunkelberg; Carol Moss
Journal:  J Med Screen       Date:  2014-06-23       Impact factor: 2.136

3.  Measurement in comparative effectiveness research.

Authors:  Jessica Chubak; Carolyn M Rutter; Aruna Kamineni; Eric A Johnson; Natasha K Stout; Noel S Weiss; V Paul Doria-Rose; Chyke A Doubeni; Diana S M Buist
Journal:  Am J Prev Med       Date:  2013-05       Impact factor: 5.043

4.  Clinical trial protocol of the ASTER trial: a double-blind, randomized, placebo-controlled phase III trial evaluating the use of acetylsalicylic acid (ASA) for enhanced early detection of colorectal neoplasms.

Authors:  Kaja Tikk; David Czock; Walter E Haefeli; Annette Kopp-Schneider; Hermann Brenner
Journal:  BMC Cancer       Date:  2018-09-24       Impact factor: 4.430

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.